Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mabylon
Well-Funded Chinese Venture Races To Clinic Amid Reviving CNS Interest
SciNeuro’s latest in-licensing deals include three assets for major neurodegenerative diseases from Lilly and Mabylon, but the Chinese bioventure is looking beyond the shopping spree at what it sees as outstanding CNS needs.
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.